Optimal management of immune-related adverse events associated with PD-1/PD-L1 inhibitors immunotherapy
HUANG Le-fu
DI Yan
XU Xiao-han
SUN Yuan-yuan
WANG Miao-miao
HE Zi-xuan
JING Ju
ZHOU Xin-na
WANG Xiao-li
REN Jun
Abstract：Immunotherapy has become an important anti-tumor means following surgery, radiotherapy and chemotherapy. (PD-1) and PD-1 (PD-L1) immune checkpoint blockers have made a breakthrough, the US Food and Drugs Administration (FDA) has approved the use of nivolumab and pembrolizumab for the treatment of malignant melanoma and nivolumab for squamous non-small cell lung cancer, urothelium carcinoma, etc. However, as PD-1/PD-L1 blockers become more widely used clinically, the inevitable more immune-related adverse events (irAEs) should be addressed. In this paper, immune-related adverse effects of PD-1/PD-L1 blockers in various organs and the corresponding clinical treatment methods are reviewed, which will help clinicians to diagnose, prevent and treat their related adverse reactions.
Keywords：Immune checkpointPD-1PD-L1Adverse eventImmunotherapy
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 177-182 )